About My Health Careers Internship MedBlogs Contact us
Medindia LOGIN REGISTER
Advertisement

Sorafenib Shows Promise in Treating Advanced Differentiated Thyroid Cancer Patients

by Kathy Jones on June 4, 2013 at 10:12 PM
Font : A-A+

 Sorafenib Shows Promise in Treating Advanced Differentiated Thyroid Cancer Patients

Results of a randomized phase III trial indicate that the kidney and liver cancer drug sorafenib holds metastatic thyroid cancer at bay for nearly twice as long as a placebo.

The trial will be presented today by a researcher from the Abramson Cancer Center and the Perelman School of Medicine at the University of Pennsylvania in a plenary session during the American Society of Clinical Oncology's annual meeting (Abstract #4).

Advertisement

If approved for use in thyroid cancer patients by the Food and Drug Administration, sorafenib (Nexavar), a kinase inhibitor that mediates tumor cell division and growth of tumor blood vessels, would be the first effective agent for this patient population. Thyroid cancer is highly curable through surgery and radioactive iodine treatment, but about 10 percent of the 60,000 patients who are diagnosed with the disease each year fail to respond to standard therapies, with tumors eventually appearing in the lymph nodes, bones, lungs, and other sites. The only other drug for advanced thyroid cancer, doxorubicin, which was approved in 1974, is not used because it is highly toxic and is not effective.

"Until we began using sorafenib, we had no medical options for these patients who suffered due to progression of their disease," said Marcia S. Brose, MD, PhD, an assistant professor of Otolaryngology and Head and Neck Surgery and Hematology/Oncology, who led the study, which is known as DECISION. "Now, we can give patients hope - a breakthrough medication that can stop the progression of the disease for 5 months. This trial is the first step in a promising series of clinical trials to identify new drugs that are shifting the horizon for patients with advanced thyroid cancer."
Advertisement

Of the 417 metastatic thyroid cancer patients studied in the multicenter, international trial, 207 were randomized to take sorafenib, an oral drug, and 210 to a placebo arm. Twelve percent of patients experienced tumor shrinkage in the sorafenib arm, compared to 0.5 percent of patients taking a placebo. Importantly, the therapy also appeared to thwart disease progression even among many of those whose tumors did not regress: 42 patients who took sorafenib had stable disease after six months, compared to 33 percent of those in the placebo group.

Among patients taking sorafenib, median progression-free survival was 10.8 months, compared to 5.8 months among the placebo group. Patients taking the placebo were allowed to cross over into the sorafenib arm once their disease progressed; 70 percent of them did so. Overall survival data is not yet available.

The most common adverse events observed among patients taking sorafenib included hand-foot skin reaction, diarrhea, alopecia, rash, fatigue, weight loss and hypertension, all of which are consistent with findings from previous trials of the drug for its approved indications.

Brose will present her team's findings in the ASCO press conference at 7:30 a.m. CT on Sunday, June 2 in Room E353a, McCormick Place in Chicago. She will also present the findings of the trial in a plenary session 3:20 p.m. on Sunday in N Hall B1 of McCormick Place.



Source: Eurekalert
Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Advertisement
News Category
What's New on Medindia
Turmeric: Magic Ingredient to Keep you Healthy in Winter
Top 7 Benefits of Good Oral Hygiene
Healthy and Safer Thanksgiving 2021
View all

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Iodine Deficiency Disorder Hyperthyroidism Hypothyroidism Leukemia Cancer and Homeopathy Chronic Myeloid Leukemia Acute Myeloid Leukemia Acute Lymphoblastic Leukemia Cancer Facts Cancer 

Recommended Reading
Thyroid Cancer
"Shaped like a butterfly she sits within the neck," that's what an anonymous poet wrote about the .....
Screening Tests for Thyroid Dysfunction
High or low thyroid stimulating hormone (TSH) level is indicative of a dysfunctional thyroid....
Hyperthyroidism
Hyperthyroidism is a condition in which the thyroid gland makes excessive thyroid hormone. Grave's ....
Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) is the cancer of white blood cells characterized by excess lympho...
Acute Myeloid Leukemia
Acute myeloid Leukemia, more popularly known by its abbreviated form AML, is a fast- evolving leukem...
Chronic Myeloid Leukemia
Chronic myeloid Leukemia is one of the most common types of blood cancer. It is characterized by ex...
Hypothyroidism
Symptoms of hypothyroidism are often general, unspecific changes in the body. Lethargy, weight gain,...
Iodine Deficiency Disorder
To control IDD, the ‘National Goiter Control Program (NGCP)’ was launched which was later renamed as...
Leukemia
Encyclopedia section of medindia gives general information about Leukemia...

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment. Full Disclaimer

© All Rights Reserved 1997 - 2021

This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use